Spots Global Cancer Trial Database for ly3023414
Every month we try and update this database with for ly3023414 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of LY3023414 and Necitumumab in Squamous Lung Cancer | NCT02443337 | Non-small Cell ... | LY3023414 Necitumumab | 18 Years - | Eli Lilly and Company | |
| Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer | NCT02549989 | Endometrial Can... Recurrent Endom... | LY3023414 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Master Rollover Protocol for Continued Safety Assessment of Study Drug | NCT02632994 | Cancer | LY2503029 LY3023414 | 18 Years - | Eli Lilly and Company | |
| A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread | NCT02057133 | Breast Neoplasm... | LY2835219 Letrozole Anastrozole Tamoxifen Exemestane Everolimus Trastuzumab LY3023414 Fulvestrant Pertuzumab Loperamide Endocrine thera... | 18 Years - | Eli Lilly and Company | |
| A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma | NCT02981342 | Pancreatic Duct... | Abemaciclib LY3023414 Gemcitabine Capecitabine | 18 Years - | Eli Lilly and Company | |
| Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer | NCT02549989 | Endometrial Can... Recurrent Endom... | LY3023414 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer | NCT02124148 | Neoplasm Metast... Colorectal Neop... Breast Cancer | Prexasertib Cisplatin Cetuximab G-CSF Pemetrexed Fluorouracil LY3023414 Leucovorin | 18 Years - | Eli Lilly and Company | |
| A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma | NCT02981342 | Pancreatic Duct... | Abemaciclib LY3023414 Gemcitabine Capecitabine | 18 Years - | Eli Lilly and Company | |
| Master Rollover Protocol for Continued Safety Assessment of Study Drug | NCT02632994 | Cancer | LY2503029 LY3023414 | 18 Years - | Eli Lilly and Company | |
| A Study of LY3023414 in Participants With Advanced Cancer | NCT01655225 | Advanced Cancer Metastatic Canc... Non-Hodgkin's L... Metastatic Brea... Malignant Mesot... Non-small Cell ... | LY3023414 Midazolam Fulvestrant Pemetrexed Cisplatin Abemaciclib Letrozole | 18 Years - | Eli Lilly and Company | |
| A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread | NCT02057133 | Breast Neoplasm... | LY2835219 Letrozole Anastrozole Tamoxifen Exemestane Everolimus Trastuzumab LY3023414 Fulvestrant Pertuzumab Loperamide Endocrine thera... | 18 Years - | Eli Lilly and Company | |
| A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) | NCT02079636 | Carcinoma, Non-... | Abemaciclib Pemetrexed Gemcitabine Ramucirumab LY3023414 Pembrolizumab | 18 Years - | Eli Lilly and Company | |
| A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) | NCT02079636 | Carcinoma, Non-... | Abemaciclib Pemetrexed Gemcitabine Ramucirumab LY3023414 Pembrolizumab | 18 Years - | Eli Lilly and Company | |
| A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer | NCT02407054 | Prostate Cancer... | LY3023414 Enzalutamide Placebo | 18 Years - | Eli Lilly and Company | |
| A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer | NCT02407054 | Prostate Cancer... | LY3023414 Enzalutamide Placebo | 18 Years - | Eli Lilly and Company | |
| A Study of LY3023414 in Participants With Advanced Cancer | NCT01655225 | Advanced Cancer Metastatic Canc... Non-Hodgkin's L... Metastatic Brea... Malignant Mesot... Non-small Cell ... | LY3023414 Midazolam Fulvestrant Pemetrexed Cisplatin Abemaciclib Letrozole | 18 Years - | Eli Lilly and Company |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
